Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses

Emergex Vaccines Holding Limited has announced promising results from a Phase I clinical trial conducted in Switzerland for their T cell-priming immune set-point candidate, known as CoronaTcP™. The purpose of the trial was to evaluate the safety and reactogenicity of CoronaTcP™ in healthy volunteers, and the findings indicate that it was generally well-tolerated by participants. Additionally, th..